Sexual function in young women with spontaneous 46,XX primary ovarian insufficiency
Loading...
Date
Authors
Kalantaridou, S. N.
Vanderhoof, V. H.
Calis, K. A.
Corrigan, E. C.
Troendle, J. F.
Nelson, L. M.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Type
Type of the conference item
Journal type
peer-reviewed
Educational material type
Conference Name
Journal name
Fertil Steril
Book name
Book series
Book edition
Alternative title / Subtitle
Description
OBJECTIVE: To assess sexual function in women with spontaneous 46,XX primary ovarian insufficiency after at least 3 months of a standardized hormone replacement regimen. DESIGN: Cross-sectional cohort, controlled. SETTING: National Institutes of Health Clinical Research Center. PATIENT(S): Women with primary ovarian insufficiency (n = 143) and regularly menstruating controls (n = 70). INTERVENTION(S): Self-administered questionnaires, 100 microg/day E(2) patch, oral medroxyprogesterone acetate 10 mg for 12 days each month for patients. MAIN OUTCOME MEASURE(S): Derogatis Interview for Sexual Function Self-Report (DISF-SR). RESULT(S): Women with primary ovarian insufficiency had significantly lower DISF-SR composite scores compared with control women. Their serum total testosterone levels were significantly correlated with DISF-SR composite score, although this accounted for only 4% of the variance in this measure. Patients with testosterone levels below normal tended to have lower DISF-SR composite scores. Of patients with primary ovarian insufficiency, 9 of 127 (7%) scored below the second percentile on the composite sexual function score, compared with 1 of 49 control women (2%). CONCLUSION(S): As assessed by the DISF-SR, sexual function is in the normal range for most young women with 46,XX spontaneous primary ovarian insufficiency who are receiving physiologic E(2) replacement. However, as a group, these young women score significantly lower on this sexual function scale than control women.
Description
Keywords
Administration, Cutaneous, Administration, Oral, Adult, Cross-Sectional Studies, Double-Blind Method, *Estrogen Replacement Therapy, Estrogens/administration & dosage, Female, Gonadal Dysgenesis, 46,XX/*complications/genetics, Humans, Medroxyprogesterone Acetate/administration & dosage, Primary Ovarian Insufficiency/*drug therapy/genetics/physiopathology, Prospective Studies, Questionnaires, Sexual Behavior/*drug effects, Sexual Dysfunction, Physiological/genetics/physiopathology/*prevention & control, Testosterone/blood, Treatment Outcome, Young Adult
Subject classification
Citation
Link
http://www.ncbi.nlm.nih.gov/pubmed/17961560
http://ac.els-cdn.com/S0015028207032220/1-s2.0-S0015028207032220-main.pdf?_tid=480558dd76c8edb1902b9bccd4054684&acdnat=1333463344_82d769fa73ca20250f7aee4d23f4d51a
http://ac.els-cdn.com/S0015028207032220/1-s2.0-S0015028207032220-main.pdf?_tid=480558dd76c8edb1902b9bccd4054684&acdnat=1333463344_82d769fa73ca20250f7aee4d23f4d51a
Language
en
Publishing department/division
Advisor name
Examining committee
General Description / Additional Comments
Institution and School/Department of submitter
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής